and psychomotor seizures (4, 5) , schizophre nia (6), schizoaffec t ive d iso rder (6) , pain syndrom es (5, 7) , and bord erlin e personality di sord er (8) . Addition all y, in 1966 Br aunhofer a nd Zicka report ed th e a n t idiu re tic effect of (C BZ) in neurohypophysial di ab et es insipidus (9) . Unfortunat ely, t he a n t id iu re tic effect of C BZ ca n signifi cantly co m plica te th e effec t ive ne ss of C BZ for th e treatm ent of psychiatric disord er s by producin g hypon atrem ia. Nu merous case re po rts (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , studi es (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) , an d two reviews (33, 34) have clearly document ed th e pr obl e m ; however, litt le co nse ns us prevail s towards underst anding eit her th e mech an ism or pr edisposing ca uses for CBZ-induced hyp on atremia.
In this study, we pr esent four wom en , middl e to elde rly in ag e, who dem onst ra te d hyponatremia aft er a short duration of C BZ th erapy. Of sig nificance is th e fact that a ll four wom en had pr eviou s m edi cal co m plica t ions, a nd fu rt he rmore, two were hyp onatremic prior to CBZ th erap y. Thus, m edi cal co m plica tions, es pec ia lly a prior a bno r mality of os mo regula t ion were obse rve d to be associa ted with hypon atreWhen th is study wa s wr itten, D r. G a nd e lman a nd D r. J oh nson wer e resid ent s in th e Dep artm ent of Psychiat ry, D r. Dab ora was a th ird yea r m ed ica l student , a nd Dr. Rib a was an Assist a nt Profess or of Psychi atry a t t he U nive rs ity o f Conne cti cut. Prese n tly Dr. G and elm a n is a n Assist ant Professor of Psych iat ry a t Yal e U niv ersi ty, whereas the other C o-authors are pu rsuing ca ree rs in th eir chose n m edi cal spe cia lt ies. m ia seconda ry to C BZ th erapy in th ese case reports. Howeve r, du e to th e sma ll number of pati ents a nd th e un controlled nature of t his stud y, we are not sug ges ting th at m edi cal co m plica t ions, es pec ia lly in os mo regu lat ion, represe nt a stat istica lly sig nifica nt associat ion wit h C BZ-ind uce d hypon at re mi a .
CASE REP ORTS
Case J Mrs. A, a 68 yea r old wom an with a diagnosis of major depression with psych ot ic fea tures, was ad m itted to the in pa ti e nt psychi atry un it a t th e Universit y H ospi ta l with a 5 day hist ory of det eriorat ing symptoms wh ich included: depress ed mo od , socia l withdrawa l, in som nia, poor a ppe t ite, feelings of guilt a nd hopel essness, m ood co ng rue nt a ud itory hallucin at ions, and religious de lu sions. The patient had been a nursing home resident for 13 years a nd had a long history of re current major depression wit h psychotic features and chronic medi cal probl e ms. On ad m ission , the pat ient was rec eiving th e following m edi cations: ph enobarbital (30 m g each morning a nd 60 mg at nigh t), tra zod on e 200 mg at nigh t tim e, di az epam 5 mg three tim es dai ly a nd NP H insulin 12 units eve ry morning. Admitting la bs were as follows: se rum sodi um 131 meq / I, (hypo nat re rnic): serum chloride 98 meq /I , se ru m potassium 4.5 me q / I, serum CO 2 28 meq / l, blood ur ea nitrogen 6 m g /d l, se ru m crea t inine 0.6 mg /dl , se ru m g lucose 102 mg /dl, a nd ph enobarbital leve l 25 mg/1. Liver fun ction t ests, hem at ologic, a nd th yr oid studies were normal. A head CT sca n revea led som e ce re bra l a nd cereb ellar at rophy as well as a n old infarct in th e left frontopari eta l lobe. An EEG showed diffuse symm etric a nd excessive fast act ivity, but no epilept ifor m foci.
Ph e noba rbital was tapered slowly, and th en C EZ wa s sta rted to tr eat both th e seizure disorder a nd th e affective illn ess , a nd tit rat ed to a dos age of 600 m g per day. The patie nt was medically st abl e during th e cha nge -ove r peri od a nd was th erap eutic on C EZ a fter seve ral days (leve l of 7 m g / I). Sin ce th e pat ient was st ill co m pla ining of a ud ito ry hallucin ations, hal op e rid ol 2 m g three times dail y was adde d to th e regim en . One week la te r , thi s pati en t was in an ac ut e confus iona l st at e, ori ent ed on ly to person, drowsy, incontinent of urine, had slurred speech , and could no longe r rem ember the nam es of st aff member s. Laborat or y st ud ies revea led th at t he pa tient's serum sodium level had dropped sig nifica nt ly to 119 meq /1. All rem a ini ng lab oratory st ud ies we re unremarkable including th e CEZ level (7 m g/ I). The se rum os mo la lity on th e following day wa s 247 mOsm /kg (nor mal = 275-295 i\Iosm /kg) a nd uri ne osmolality measured 2 days lat er was 255 Mosm /kg with a urine sod ium of 68 me q / 1. The C EZ was di scontinued a nd th e patient was fluid restrict ed . Du e to th e patient 's past hist ory of a seizure di sorder, th e patient was sta rted on ph en ytoin whi ch was t itrat ed up to a dose of200 mg tw ice dai ly. The delirium cleared to her pr eviou s baselin e ment a l sta t us two da ys afte r sto pping the CEZ, a nd th e serum sod ium gradually increased to 133 meq / I over th e next week .
Case II
.'vII'S. E, a n 80 yea r old wom en , with a n a pproxima te 60-year histo ry of bipo lar disorder, pr esent ed to th e e me rge ncy ro om ex pe rie nc ing a relapse of her prim ary a ffect ive d isorde r. On pr es entation, th e patient described a I week history of a hypom ani c e pisode cons ist ing of th e following symptoms: m idd le insomnia, eleva te d mood, grandiose id eation, incr eas ed e nergy, a nd incr eased sex ua l pr eoccupation . In add it ion, sh e described drinki ng a pproximately I a lcoho lic dri nk pe r day. P ri or to admission the patient's m edi cations included : lova st at in 1 mg tw ice d a ily, a nd t riavil 2-10 (2 m g perphenazine and 10 mg amitriptylin e) on e tabl e t in t he morning a nd two tablet s at night.
On adm ission the patient's m anic e pisode was co n t rolled with low doses of bot h ha lop e rid ol a nd lorazep am . Ad m ission lab s revealed the follow ing: sod iu m of 134 m eq / I (h ypon atremic) , potassium 01'4.5 meq / I, ch lor ide 99 m eq / I, CO 2 27 m eq /I, gluc ose 104 m g /d l, crea ti ne 0.7 mg /dl a nd blood ur ea nitrog en II m g /dl, norm al liver fun cti on test s, norm a l thyr oid a nd hem atology studies. C BZ treatm ent was initiat ed a nd titrat ed to 200 mg twi ce d ail y; how eve r, t h ree d ays a ft er ini t iati ng C BZ, the pati e nt tr ip ped and suffe red a mild con t usion of he r left for eh ead. Laboratory a nd radio logi c st ud ies were o rde re d with th e foll owin g result s: sod ium 125 rneq / I, pot assium 4.8 m eq /I , ch lo rid e 9 1 m eq /I , CO 2 26 m eq /I , a nd a no rm a l head CT sca n. Att empts we re mad e to continu e the C BZ t reatm ent whi le m an a gin g this ac u te exa cer ba t ion of the hy ponatremia with fluid restriction, 1500 ml /day. The pat ie nt 's sod iu m level fluctu ated between 122 a nd 13 1 m eq /I with serum os mo la lity of 265 mOsm / l, req uir ing the di scontinuation ofCBZ II days a fte r init iation . O ver the next 2 week s the pa ti ent 's sod iu m level s followed an upwa rd tr en d a nd a t dis charge , th e level was 133 m eq /] .
Case III
Mrs. C , a 54 year old m ent all y re tard ed fem al e, with a lon g h ist ory of ch ro nic u ndi ffe re ntia ted schizop h re n ia requiring num erous hospitali zation s, wa s transferred from a sma ll co m m u nity hospit a l to th e Un ivers ity Ho spit al. T he sc hizo ph re n ia had been m an a ged e ffectivel y wit h a n t ipsyc ho tic m edication ; however, du e to th e fa ct that th e patient 's pr ior sym p to ms sugges te d a neuroleptic m ali gn ant synd ro me (e leva te d temperat u re o f 100°F a nd crea tine kinase of 343 U / I) th e ph ysicians a t th e co m m u nity hospit al felt u nco m fo rt ab le managing the patient with ne uro leptics . H er m edi cation s on tr an sfer we re as follows: thioridazine 25 mg twi ce d ail y, clona ze pa rn I m g twi ce d ail y, a lp razola m 0.25 mg three t imes daily, dicloxa cillin sod iu m 500 m g four tim es d a ily, g lipizid e 25 mg d ail y, sod iu m docu sa te 200 mg daily, and iron su lfa te 325 m g tw ice da ily.
On pr es ent ation t he patient wa s highly a g ita te d, required fo u r poin t rest ra in ts, a nd rem ained a cut ely psych otic. The patient wa s initiall y m ana ged with lora ze pa m , I mg th re e tim es d ai ly, g lyburide 2.5 m g d ail y, iron sulfat e 325 m g twi ce d ail y, a nd docu sat e 100 m g twice daily. Admission la bo ra tory va lu es were as follows: g lucose 124 m g/dl , urea nitrogen II m g /d l, crea tinine 1.0 m g /dl , sod iu m 142 me q /I , pot a ssiu m 4.4 m eq /I , ch lor ide 105 m eq / I, CO 2 27 m eq /I , ioni zed ca lciu m 1.37 mm ole /I (sligh t ly el eva t ed) . The liver fu ncti on test s, th yro id fun ction , a nd hematologic la bo rat ory st udi es were a ll within th e normal ran ge. A neurolog ica l wor k up revea led a norm a l EEG a nd he ad CT sca n. One we ek followin g th e neu ro logical eva lua t io n, the patient ex pe rie nce d two ge neralized tonic clon ic se izu res ea ch u nd e r 60 seconds . A more in d epth neurological eva lua t ion wa s ini ti at ed ; howeve r, again a ll result s wer e no rmal. C BZ was start ed an d th e doses were incr ea sed slowly ove r a fou r week pe riod u n til a th erapeutic level of 8.0 mg /I wa s ob taine d . Approximat ely two wee ks a fte r reach ing a the rap eutic level , a sod iu m of 127 m eq /I wa s no ted. The pa ti e n t com pla ine d of be ing lig h t head ed and having difficulty ambu lating. During this period o f hypon at remi a, urine os mo la lity wa s 447 mOsm / kg and se ru m os m ola lity wa s 267 mOsm /k g (no r m a l ra nge 275-295) . Ph e nyt oin wa s subs t it u ted for C BZ a nd within one wee k the pa t ie nt 's sod iu m normal ized .
Mrs. D, a 58 yea r old whit e fem ale , with a n a pproxima te ly 20-year hist ory of a schizoaffective di sorder was ad m itted to th e U nive rs ity H ospit al a fter a n acu te exacerbation of her psych oti c illn ess. The patient 's schizoaffect ive di sorder had been managed with low do se neu rol eptics, fluph en a zin e 5-10 mg per day a nd lithiu m carbo na te . Six months prior to th e ad m ission, she describ ed a pro gressive re turn of typical symp toms: isola tion, pers ecutory de lusion s, messa ges fr om th e tel evision , delu sion s of referen ce, poor conce nt ration, insomnia, po or appetit e, low mood , le t ha rgy, a nd sui cid a l idea t ion . On pr esent at ion t he pati ent was irritable, a nxious, a nd gua rde d . Th e admission la bora tory eva lua t ion; sod ium 143 meq /I , g luco se 117 mg /dl , pot assium 4.4 meq /I , chlor ide 116 meq /I, C O 2 22 meq / I, liver function test s, th yroid st ud ies, a nd hem at o logy st ud ies; was norm al.
She was ini ti all y m an aged with flu ph en a zin e 5.0 mg twice da ily and th en swit ch ed to m olindon e 20 mg twice dail y, ben ztropi ne 1.0 m g o n a n as needed basis, and lora ze pa m 1.0 mg on a n as need ed basi s. Du e to th e refract ory na ture of Mrs. C's th ou g ht disorder, CBZ was adde d a nd increased to 200 mg three times dail y. Rout ine lab or at or y stu d ies were order ed 5 days afte r having reach ed a C BZ do se 01'200 m g three times daily, a nd were sign ificant for a sodium of 122 meq /I , crea t inine 0.8 mg /dl, pot assium 4.5 meq /I, chloride 90 meq /l and CO 2 24 meq /1. The C BZ was di scontinu ed seco nda ry to th e hypon atre mi a a nd after I week th e patient 's hypon atremia resolved .
DI SC USSION
In th is paper, we report 4 case s of C Bl-associated hyponatremi a in four midd le-aged to e lde rly females, a ll who have m edi ca l co m plica tio ns. T wo cas es are rem arkab le in th at th e pr etreatm ent sod iu m levels dem on strat e hypon a t re m ia ; however, eve n th ese low sodiu m leve ls were sig nifica n t ly d ecr eased by C Bl. Due to th e fact th at th ese a re isolated reports, few d efinitive conclusio ns can be mad e, althou gh sim ila rities in th es e cases sho uld be exa m ine d. First, a ll pa tients are midd le-aged to e lde rly fem a les. Sec o nd, a ll four wom en have m edi cal proble ms; furth ermore, two have abnormal osmoreg ulation as defin ed by pr e-exi sting hypon atrem ia . Third, a ll patients were using conc u r re n t m edi cation s, es pec ia lly an tipsycho tic m edi cations , and a ll pr esent ed with psych oti c sym pto ms. These case st udies highlight th e fact that C Bl -ind uce d hypon atremia represe nt s a serious sid e effect whi ch m ay not be as rare as pr eviou sly th ou ght.
Nu me ro us ca se s, mo stly associa te d with neurological di sorders, d escribi ng CBlinduced hyponatremia have been report ed in th e lit erature over th e past 20 years (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Again no conclusions ca n be drawn du e to th e sm a ll sa m ple size; howeve r, some ge ne ra liza t ions ca n be described. First , mo st pati ents a ppear to be over 40 years old; althou gh a case rep ort by Palladino ( 15) describes a 20 yea r old male with hyponatremia . Second, a ll pati ents a re su ffering from a ne u ro logical/psychiatric di sease. Third, many of th e pati ents a re tak ing ot her m edi cation s in conjunction with C Bl . Fourth, th e tim e period required fo r th e o nse t of hypon atremia followin g initi ation of CBl th erapy is difficult to asce rt a in, as man y of th e case rep o rt s d eal with lo ng term admini stration of CBl. Fifth, recovery fro m hypon at rem ia occu rs followin g wit hd ra wa l ofCBl. In su m mary, th e pool ed qu an tit ative da ta from t he case reports a re as follow s: ran ge of age was from 20 to 80 yea rs, ra ng e of C Bl per day was between 400-1200 mg, a nd levels ran ged from 4.4 to 15 m icr og ra ms per lit er.
Even in large r clinica l studies (23-3 2) , few definiti ve conclusions ca n be m ad e conce rn ing CBl-induced hypon a tremia , since th e d at a among studies a re ofte n con t radicto ry. Again for th e sam e rea so n cite d a bove minim al da t a exists on t he time cou rse of CBl-induced hypon atremia . The ove rall incid en ce ra t e of CBl-induced hyponatremia is d ifficult to ascerta in, since t he study popul at io ns from th e man y a r t icles a re not homogen eou s. Thus, th e dat a ca n not be summ ed , and a range of 0-33% for th e incid ence rat es of CBl-induced hyp on atrem ia is th e onl y d escriptive st ati sti c whi ch ca n be report ed .
Th e sym pto ms of hyponatremia or wat e r int oxicat ion when plasma sod iu m fall s below 120 m illieq uivale n t per lit e r (meq / I) inclu de: dizziness, headach e, lethargy, m ent al confus ion, men tal slowing, weak ness, loss of apa tit e, and hosti lit y. Neu rologica l ab no r malit ies, st upor, co nvulsions, a nd coma, dom ina te as th e sod ium level fall s below 110 m eq /I (33 ). Mu ch of th e difficulty conce rn ing th e iden t ifica t ion of C Bl-ind uce d hyp on atremia involves th e high percent a ge of asymp tomati c individ uals with hypon a tremi a. In this case report , only hal f t he pati e n ts were sym p to ma tic, a nd in o t he r case rep or ts by O 'Ha re e t a l. (30) and Kal ff and cowo r ke rs (22) eve n th e most seve re ly affected hypo natrem ic pa ti en ts we re asymptom atic. An add it iona l com plica t ion in th e clinical d ia gn osis of C Bl-ind uce d hypo na t re m ia occurs from th e overla p of sym pto ms rel ating to C Bl in to xica t ion . In su mmary, few definitive facts ca n be asce rtaine d a bo ut th e side effect of C Bl -ind uced hypona t re m ia. First , th e ti m e course of C Bl -induced hypona t re mi a is poo rly defin ed and m ay occur afte r ch ro nic ex pos u re . Second, th e incide nce ra te varies from 0-33%. Third, hyponatremi a has clearly defin ed sym pto ms; howeve r m an y pa t ien ts remain asym pto ma t ic a t sod iu m levels be low 116 m eq /1.
An exam ina t ion of th e C Bl-ind uce d hyp on atre mi a lit e ra t ure reveal s num erou s st udies wit h little conc u r re nce on eit he r ris k factors or me chanism of CBl-induced hyponatre mi a . For exam ple, stu dies by Kal ff a nd cowork ers (22) a nd Lahr (23) identify age as a n import ant risk fact o r; wh ereas num e ro us studi es (24-31 ) do not d em on strat e a co r re la t ion bet ween age a nd C Bl-ind uce d hyponat re m ia. Simi larl y, C Bl se rum levels have been associa te d wit h hypo na t re m ia in st ud ies by H enry and cowo r ke rs (27) , La hr (23), Ka lff an d colleagues (22) , O ' Hare a nd associat es (30) , while H eli n a nd coworke rs (25) , joffe and associat es (29) , and Vieweg a nd cowor kers (32) have no t obse rve d a re lat ions hi p be tween C Bl serum levels and hypon at remi a.
Lastly, on ly Kalff a nd cowo r ke rs (22) a nd Yassa a nd co lleagues (31) describe a n associat ion of polyph arm acy a nd C Bl-ind uced hypon a t re m ia . T hus, eve n a n ex ploration of t he previous ly com plet ed studies on C Bl-induced hyponatremi a fail s to consistently revea l risk facto rs for th e d eve lopment ofC Bl-induced hypon atremi a .
In a similar manne r, th e st udi es exa m ining th e pharmacological mech ani sm s responsibl e fo r C Bl-i nd uce d hypon atremia fail to elucidat e any gen eral conse ns us.
One cou ld specula te on th e m ech ani sms of C Bl-induced hypona t re m ia , i.e ., C Blinduced hype rse cretion of anti-diuretic hor m one (ADH), a direct ac tion of C Bl on re nal tu bules, a pos itive syn e rg ist ic act ion of C Bl and ADH o n ren al tu bul es, a CBZ-induced decr ea se in osmoreceptor sensit ivit y to sod iu m, or lastl y a C BZ-induced resetting of th e os mo rece pto r thresh old for sod ium . Frah m and colleag ues (35) , Kimu ra a nd associa tes (36) , and Asht on a nd cowo r kers ( 10) pr esent evide nce cons iste n t with a CBZ-induced hypersecr etion of ADH; howeve r, both Frahm a nd coa u t ho rs (35) a nd Kimura and colle ag ues (36) use a bioassay, t he hydrat ed rat , whi ch m easures ac t ivity and not conce ntra t ion of ADH. Co nversely, Ka lff and ass ocia tes (22) , G old a nd cowor ke rs (37) , S te phe ns a nd coa u t hors (38) , Meinders a nd colleagues (39) a nd Thom as a nd associa tes (40) do not su pport t he findin g th at CBZ incr ea ses ADH sec re tio n. Furtherm or e, th ese st udies e m ploy radioimmunoa ssay (RIA) whi ch a t te m p ts to dir ectl y det ermine th e co nce n t rat ion of AD H , and consequ ent ly, t hese st ud ies con tain a more re liab le assa y for ADH as com pared with a bioassay. M einders a nd associa tes (39) conclude in th eir st udy th at C BZ sensitizes o r ac ts direct ly o n th e renal tubules t o produce a positive synergis tic effec t with ADH . A decr ease in os morece p tor se ns itivity to sod iu m (t he la zy re ceptor hypothesis) was cons iste n t with th e dat a from ind epend ent st udies don e by both Go ld and coa u t ho rs (37) a nd St eph ens cowor ke rs (38) . In addition, th ese two st ud ies proposed t hat CBZ m ay a lso have a direct effec t o n ren al tubular ce lls. Co nve rse ly, T homas a nd assoc ia tes (40) d educed fr om th eir dat a th at C BZ rese ts th e osmoreceptor thresh old for ADH a nd docs not affect th e se ns itivity of th e os morece ptor. T he mo st proba ble m ech anism of C BZ-ind uce d hypon atremia involves so me type of C BZ-d ir ect ed osm orece ptor perturbation, since th e s t udies impli cating this m ech anis m were more rigorou s a nd co m ple te d with more mod ern assay m ethod ology. Howeve r, two of t he s t ud ies th at implicat e C BZ-d irec te d osmorece p tor dysfun cti on, a lso reveal conc urrent evide nce of a C BZ effec t on ren al tubul ar ce lls. At pr ese nt t he e t iology and risk fact ors associa te d with CBZ-induced hyp on at remia rem ain poorl y defined , and th us , furth er st ud ies will be need ed to e luc id a te th e m ech anism of CBZ-induced hypo na t rerma .
Our int erest in this topi c was initiall y st im ula te d by four in te resting cases . Althou gh a ll four cases had num e rou s fact or s in com mo n; suc h as female sex , ch ro nic m ed ical pr ob lems (including pr e-exi st ing hyp onat remia ), concu rre n t use of medi cations (es pec ia lly antipsych oti c m edi cations) , a nd initial psych oti c presen t a tio n; t he lite ra t u re do es not su ppor t an y of th ese cha rac te rist ics as risk fact or for developing C BZ-ind uce d hypon atremia . Two of th e four pat ients we re asymp tomatic with sodiu m level s below 130 m eq /l , a n obse rva t io n co m mo nly not ed in t he lite ra t ure. Conse q ue n t ly, elec trolyte m onit oring of pati ents t aking C BZ is necessita t ed . In co nclus ion, th e case reports, clini cal st ud ies , a nd m ech ani sti c st ud ies often yield conflict ing dat a co nce rn ing CBZ-induced hyponatremi a ; how ever, th e occurren ce of C BZ-ind uce d hypon atremia is well document ed , a nd thus, phys icia ns usi ng C BZ mu st monit or (bo t h clinica lly a nd with e lec t ro lyte st ud ies) th eir pa ti ents for thi s dange rou s side effec t.
